SOT Science News Alert August 2013
Below are a number of SOT-sponsored meetings and events that may be of interest to you. For more information, contact the organizers directly.
Environmental Mutagenesis and Genomics Society 44th Annual Meeting—Late Breaking Abstract
Deadline is August 28, 2013
The Environmental Mutagenesis and Genomics Society (EMGS) is the primary professional society for scientists involved in research into environmental causes and consequences of damage to the genome and epigenome. The 44th Annual Meeting will be held September 21–25, 2013, at the Hyatt Regency Monterey, in Monterey, California. This year's theme is “Embracing the Science of the Future through Cross-Disciplinary Research.” The Society’s Annual Meeting is unique in bringing together scientists who carry out basic research with those involved in risk estimation and regulatory concerns related to the consequences of exposure to environmental, industrial, and pharmaceutical agents. The result is a dynamic meeting that is sufficiently large to cover a broad range of contemporary topics, yet focused to facilitate interactions between students and renowned scientists in academia, government, and industry. This is a meeting not to be missed. For additional information, visit the EMGS 2013 Annual Meeting website.
Practical Application of Toxicology in Drug Development, September 9–13, 2013, Edinburgh Capital Hotel, United Kingdom
This course, taught by distinguished experts, is designed to provide a basic training in toxicology. Participants will obtain an overall understanding of the principles of nonclinical safety assessment of drug development with emphasis on the practical application of these principles and interpretation of nonclinical safety data. The course will include a discussion of regulatory case studies and a review of a drug application. This toxicology course is intended to benefit individuals working with small and large molecules from biotechnology and pharmaceutical companies, along with those from CROs and regulatory agencies who are interested in toxicology. Regulatory toxicology in drug development will be emphasized, particularly from the European perspective. To register and for more information, please visit the
conference website.
Safety Pharmacology Society Annual Meeting, September 16–19, 2013, Rotterdam, Netherlands
The Safety Pharmacology Society (SPS) 13th Annual Meeting will be held September 16–19, 2013, in Rotterdam, The Netherlands, and will provide a dynamic forum for sharing the latest in safety pharmacology. The scientific program offers in-depth discussion of relevant topics to keep you “in the know.” This meeting will feature a diverse range of scientific sessions organized into thematic tracks, covering issues such as, Reducing Safety Related Attrition, Expanding the Frontiers of Safety Pharmacology, Improving Support to Clinical Development, Translation of Safety Pharmacology Studies to Humans, Update and Feedback on CSRC-HESI-FDA Workshop, and a Best Practices Workshop on Comparing Safety Pharmacology as “Stand Alone” to SP-Endpoint Inclusion in Toxicology. The meeting also will offer a full day of Continuing Education courses on September 16, both on an introductory level as well as advanced courses for the expert, and the Diplomate SPS (DSPS) Certification exam will be held the day before the meeting on September 15. For preliminary meeting information, please visit the
2013 Annual Meeting Website.
Product Quality Research Institute Workshop on Nanomaterial Drug Products: January 14–15, 2014
The Product Quality Research Institute (PQRI) Workshop on "Nanomaterial Drug Products: Current Experience and Management of Potential Risks" will be held January 14–15, 2014, at the US Pharmacopeia (USP) Meeting Center, Rockville, Maryland. The overarching goals and objectives of this meeting include a review of analytical science and methods for characterizing nanomaterials and discussion of their application to the characterization and quality control of drug products. Participants will share experiences and results and discuss approaches to the management of potential risks of nanomaterials in drug products starting from early drug development and throughout product lifecycle. The implications for maintaining quality, safety, and efficacy will be highlighted. The expected outcomes are to establish opportunities for collaboration between academia, industry, and government– sponsored research programs and to develop a summary report of the workshop discussions and recommendations. For more information and to register for this meeting, please visit the
conference website.
NANOTOX 2014, 7th International Nanotoxicology Congress: Abtract Deadline January 15, 2014
NANTOX 2014 will be held April 23–26, 2014, in Antalya,Turkey.This congress continues the series of international nanotoxicology meetings that has included: 2006 Miami, 2008 Zurich, 2010 Edinburgh, and 2012 Beijing. Commercialization of emerging nanotechnologies influences societal responses to their development and applications and demands for better evaluations of their effects on the environment and human health. Sessions of the congress will highlight the hot topics of nanotoxicology with the world-leading experts in this field. Moreover, this congress will create opportunities for participants to present and share experiences, explore new directions, and debate topics with experts from across the globe in the field of nanotoxicology. The abstract deadline is January 15, 2014. For additional information, please visit the
NANOTOX 2014 website.
FutureTox II CCT: Pathways to Prediction—January 16–17, 2014
The FutureTox II:
In Vitro Data and
In Silico Models for Predictive Toxicology Contemporary Concepts in Toxicology (CCT) conference will be held January 16–17, 2014, at the William and Ida Friday Center for Continuing Education, University of North Carolina, Chapel Hill, North Carolina. The conference aims to address the pathway-based strategy by bringing together basic research into a congress that integrates newer
in vitro methodologies and computational (
in silico) modeling approaches with advances in systems biology. An overarching goal is to clarify the usefulness and validity of new and emerging technologies and approaches so that expectations can be managed in both the regulatory and regulated scientific communities. There will be ample opportunities to network with experts in this fast changing growth area.Some aspects of this topic were covered in the October 2012 FutureTox CCT meeting. This FutureTox II CCT will provide a forum for a detailed scientific discussion of how the biological pathways of interest will be elucidated, characterized, and qualified for pathway-based risk assessment. Breakout groups will address four key areas: Regulatory Toxicology, Liver Disease and Hepatotoxicity, Developmental/ Reproductive Toxicity, and Cancer. There is global interest in “Adverse Outcome Pathways” (AOPs) as a conceptual framework for mode-of-action approaches in these four areas. Focusing the CCT on scientific issues where new methodologies and advances can move us beyond reliance on animal models will benefit all researchers and regulators as a way of identifying key questions that need research. Partial travel support for graduate students and postdoctoral scholars will be available. To register and for additional information about this conference, please visit the
FutureTox II website.
SOT sponsors two types of meetings outside of the SOT Annual Meeting:
Contemporary Concepts in Toxicology (CCT) and
Non-SOT meetings. CCT meetings are one- to two-day focused, open registration, scientific meetings in contemporary and rapidly progressing areas of toxicological sciences. Non-SOT meetings are sponsored by other not-for-profit organizations and SOT will either endorse or provide sponsorship money to toxicology-related meetings.